Fresh analysis suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a prominent health publication shows that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using such treatments need to be cognizant of the potential of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting weight in about 18 months.
Comparing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
Scientists note that people who shed pounds through dieting usually see a less rapid weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Quick Regain
Nutrition scientists propose the way of the drugs is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Condition?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, given the significant potential of weight regain, the treatment should be considered long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "highlight the long-term character of obesity," comparing it to managing conditions like high blood pressure.
User Testimonies
Users who have stopped the medication explain a intense resurgence of appetite.
"I experienced something activating and I was suddenly extremely hungry," recalled an individual.
This challenge is compounded if users have not adopted lasting lifestyle or habit modifications during treatment.
Widespread Interest
Figures show that a significant number of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while these medications are potent agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on combined behavioural changes.
